Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Other Accumulated Expenses (2016 - 2024)

Historic Other Accumulated Expenses for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 16 years, with Q4 2024 value amounting to $9.9 million.

  • Lifecore Biomedical, Inc. \De\'s Other Accumulated Expenses rose 2884.94% to $9.9 million in Q4 2024 from the same period last year, while for Nov 2024 it was $9.9 million, marking a year-over-year increase of 2884.94%. This contributed to the annual value of $9.4 million for FY2024, which is 3097.17% up from last year.
  • Per Lifecore Biomedical, Inc. \De\'s latest filing, its Other Accumulated Expenses stood at $9.9 million for Q4 2024, which was up 2884.94% from $11.4 million recorded in Q3 2024.
  • In the past 5 years, Lifecore Biomedical, Inc. \De\'s Other Accumulated Expenses registered a high of $13.0 million during Q1 2022, and its lowest value of $3.0 million during Q2 2021.
  • Its 5-year average for Other Accumulated Expenses is $7.7 million, with a median of $7.4 million in 2023.
  • As far as peak fluctuations go, Lifecore Biomedical, Inc. \De\'s Other Accumulated Expenses tumbled by 6984.37% in 2021, and later surged by 14136.6% in 2022.
  • Lifecore Biomedical, Inc. \De\'s Other Accumulated Expenses (Quarter) stood at $6.1 million in 2020, then crashed by 36.55% to $3.9 million in 2021, then soared by 141.37% to $9.4 million in 2022, then fell by 18.24% to $7.7 million in 2023, then increased by 28.85% to $9.9 million in 2024.
  • Its Other Accumulated Expenses stands at $9.9 million for Q4 2024, versus $11.4 million for Q3 2024 and $9.4 million for Q2 2024.